4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q1 EPS

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($0.86), in-line with the analyst estimate of ($0.86). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $529.67 thousand.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• Microsoft: Azure West U.S. region experiences intermittent connectivity failures and latency issues
• U.S. to begin rulemaking aimed at shoring up car door safety - Bloomberg